Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2012

Conditions
Multiple Sclerosis, Chronic Progressive
Interventions
DRUG

Cyclophosphamide (drug)

IV cyclophosphamide infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.

DRUG

Methylprednisolone (drug)

Control group : IV methylprednisolone infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.

Trial Locations (26)

13385

Hôpital La Timone, Marseille

14033

CHU Caen, Caen

16470

CH d'Angoulême Girac, Saint-Michel

21033

CHU Dijon, Dijon

25030

CHU Besançon, Besançon

30029

(CHU Nîmes) Hôpital Caremeau, Nîmes

33076

Hôpital Pellegrin, Département de neurologie, Bordeaux

34295

(CHU Montpellier), Hôpital de Gui de Chauliac, Montpellier

35033

CHU Ponchaillou, Rennes

44093

Hôpital Guillaume et René Laënnec, Nantes

51092

(CHU Reims) Hôpital Robert Debré, Reims

54035

CHU Nancy Hôpital central, Nancy

57038

(CHR Metz-Thionville) Hôpital Notre Dame de Bon Secours, Metz

59037

CHU Lille Hôpital Salengro, Lille

59462

GHICL Hôpital St. Philibert, Lomme

63003

Hôpital Gabriel Montpied, Clermont-Ferrand

64046

Centre Hospitalier de Pau, Pau

64109

CH de la Cote Basque, Bayonne

67091

(CHRU Starsbourg) Hôpital civil, Strasbourg

69394

(CHU Lyon) Hôpital neurologique, Lyon

75019

Fondation Rothschild, Paris

75970

(AP HP) Hôpital Tenon, Paris

78300

CHU de POISSY, Poissy

87042

CHU Limoges, Limoges

94010

AP HP Henri Mondor, Créteil

06002

CHU Nice Hôpital Pasteur, Nice

All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

lead

University Hospital, Bordeaux

OTHER

NCT00241254 - Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis | Biotech Hunter | Biotech Hunter